These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting gly...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 45690...
Under the adaptive statistical analysis plan, should the CardiAMP Cell Therapy for Heart Failure study be stopped early for anticipated efficacy at this, o...
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...
U.S. Food and Drug Administration announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in vitro diagn...
Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...
"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidl...
The MoU was signed by Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi(DoH), Fra...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to ...
Genomill, a pioneering precision diagnostics company, brings its cutting-edge Geno1® platform to the collaboration. Genomill's proprietary and patented...
"We are very pleased about the cooperation with Novaliq, a pioneer for groundbreaking non-aqueous eye drop technology. With regard to the unique properties...
© 2025 Biopharma Boardroom. All Rights Reserved.
